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1. IMMUNOLOGICAL ASPECTS OF 
MALIGNANT TRANSFORMATION 
The meeting was opened by an introductory lec- 
ture of G. Pasternak (Berlin-Buch) summarizing 
problems of cell proliferation, differentiation and 
malignant transformation. Special attention was 
focussed on the role of one genes and one gene 
products as constituents of the ‘normal’ cellular 
genome and as functional components of a 
‘mitogenic’ cascade normally controlling cell 
growth. 
The first topic of the meeting was concerned 
with immunological aspects of cellular prolifera- 
tion and transformation. U. Karsten et al. (Berlin- 
Buch) reported preliminary results concerning the 
production of monoclonal antibodies (MoAbs) 
against syngeneic ras- or myc-transformed rat em- 
bryonic fibroblasts. 
Another topic of this section dealt with im- 
munological reactivities as a consequence of malig- 
nant alterations. G. Petranyi (Budapest) reviewed 
the functional importance of several membrane- 
bound structures (e.g. CD antigen system LFA, 
HLA DR) of functionally defined cells (cytotoxic 
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T-lymphocytes, NK cells) for target cell recogni- 
tion and possibilities of influencing the expression 
of these antigens. 
H. Fiebig et al. (Leipzig) described changes in 
membrane antigen expression by stimulated lym- 
phocyte subsets as detected by a set of MoAbs. 
Several aspects of anti-tumour reactivity were in- 
vestigated by Z.G. Kadagidze et al. (Moscow) us- 
ing MoAbs to different lymphocyte-specific 
antigens. Immunoregulatory aspects of tumour 
therapy were discussed by M. Z(iller (Heidelberg). 
The role of the regulatory activities of different T- 
cell subtypes was demonstrated in an experimental 
mouse system. Systemic antigen application ac- 
tivated a third regulatory component (contrasup- 
pressor cells) which down-regulated the suppressor 
cell activity and led to an anti-tumour reactivity. 
Another way of influencing tumour growth was 
demonstrated by V. Schirrmacher (Heidelberg). 
Using non-oncogenic, non-lytic Newcastle Disease 
viruses to infect mouse tumour cells, an an- 
timetastatic effect and tumour reduction could be 
obtained. This treatment was also effective in 
human melanoma cells growing in nude mice. An 
inhibition of tumour growth and an activation of 
killer cells was reported by J. Bubenik (Prague) 
after a local interleukin-2 (IL-2) treatment in an ex- 
perimental system. Problems in this therapeutic 
model resulted, however, from non-specific side 
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effects following IL-2 application. The importance 
of immunogenetic predisposition for resistance 
against special diseases was demonstrated by J. 
Plachy (Prague) in Rous sarcoma virus-infected in- 
bred chickens. Some aspects of non-specific killer 
cell activity (K, NK, ALK cells) in humans were 
demonstrated by P. Jantscheff et al. (Berlin- 
Buch). In some cancer patients an activated killer 
cell type (ALK cells) was detected in tumour- 
draining lymph nodes and in spleen but not in 
lymph nodes localized in other regions in blood or 
in healthy persons. M. Moore (Manchester) 
reported data about tumour-specific cytotoxic T- 
lymphocytes and the relation between the MHC 
status of cancer cells and lymphocyte recognition. 
Failure of MHC antigen expression (classes I 
and II) on cancer cells prevented the recognition of 
these cells by T-lymphocytes in autologous 
systems. There was a stimulation of lymphocytes 
only in 45% of tumour patients using a mixed 
lymphocyte-autologous tumour cell culture. The 
stimulation of lymphocytes was correlated with a 
better prognosis for these patients. 
The occurrence of tumour-associated antigens 
(TAA) and their usefulness in diagnosis were 
discussed in two reports. M. Price (Nottingham) 
reported on data obtained with the MoAb 
HCRCl 1. The MoAb defines a glycoprotein of a 
molecular mass 1400 kDa which is mainly local- 
ized on the luminal surface of mammary gland 
epithelia. This antigen was found in sera from 
about 40% of mammary carcinoma patients but 
not from healthy persons. B. Micheel (Berlin- 
Buch) reported on the production and 
characterization of MoAbs to the tumour markers 
AFP, hCG, and CEA. The possibility was dis- 
cussed of developing enzyme immunoassays using 
bispecific MoAbs (anti-AFP/antiperoxidase) 
which are produced by a tetradoma cell line which 
had been selected using an FACS after fusion of 
two hybridoma lines. 
2. GROWTH-STIMULATING FACTORS 
reviewed information on the identification of 
growth inhibitors, their mode of action, and their 
interaction with growth factors. 
M.D. Hollenberg (Calgary) suggested that EGF 
might play a role in the development of both the 
palate and the heart. Furthermore, EGF exerts 
vasoactivity in isolated arterial strips. At the 
cellular level EGF seems to regulate secretion of 
somatomedin-like growth factors by cultured cells. 
A 35 kDa substrate of the EGF receptor protein 
kinase was shown to have sequence homology with 
human lipocortin (a phospholipase 2 inhibitor) as 
well as with other proteins (calelectrin, endonexin) 
that are involved in stimulus-secretion coupling. 
J.J. van Zoelen (Utrecht) established a growth 
factor-defined assay for anchorage-independent 
growth and a serum-free assay for loss of density- 
dependent inhibition of growth for NRK cells. 
Colony formation of NRK cells in semi-solid 
media can be induced by several combinations of 
growth factors other than TGF-a, together with 
the so-called ‘modulators’ TGF-,8 or retinoic acid. 
In addition, J.J. van Zoelen identified a PDGF- 
like growth factor secreted by a mouse 
neuroblastoma cell line. 
A. Johnsson (Uppsala), after reviewing the data 
obtained together with other laboratories on the 
structural and functional homology of the SSV 
viral transforming gene product (vsis) with the 
‘normal’ growth factor PDGF, demonstrated that 
the PDGF receptor-blocker suramin, like anti- 
PDGF antiserum, blocks in vitro transformation 
of human fibroblasts by SSV. She further 
presented data that an osteosarcoma-derived 
PDGF-like growth factor is structurally related to 
a homodimer of the PDGF A-chain. 
S. Stabel (London) reported on the structure 
analysis of protein kinase C, which is believed to 
be involved in the transduction of extracellular 
growth stimuli across the cell membrane and to be 
the major cellular receptor for tumour-promoting 
phorbol esters. The complete structure of the 
bovine brain enzyme has been deduced from 
cDNA clones. It shows similarities to the structure 
of metalloproteins, and its kinase region has 44% 
identity with that of the CAMP-dependent protein 
kinase. Moreover, there seem to be at least 3 isoen- 
zyme species expressed differently in different 
tissues. 
W. Wunderlich (Berlin-Buch) reported on ex- 
The second topic of the meeting concentrated on 
the role of peptide factors in the regulation of pro- 
liferation in both normal and malignant cells. As 
well as discussing new information on the structure 
and function of some of the best known growth 
factors (TGF, EGF, PDGF), the symposium 
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periments in vitro and in vivo, which demonstrate 
that tumour promoters definitely increase the 
replication of tumour viruses in infected cells, in- 
dicating a fatal synergism between tumour viruses 
and tumour promoters. Though nothing is known 
of the underlying mechanisms, protein kinase C 
might well be involved. 
D. GltiBer (Halle) demonstrated eye lens 
epithelial cells to be an elegant model for the ex- 
amination of growth regulatory processes. He con- 
vincingly demonstrated the interdependence of cel1 
shape and growth status. 
H. Bielka (Berlin-Buch) concentrated in his 
presentation on growth regulatory events at the 
translational evel. Using in vivo (regenerating rat 
liver) and several in vitro systems, he showed that 
the capacity of post-mito~hondrial supernatants to 
stimulate cell-free translation clearly depends on 
the proliferative state of the cells used for isola- 
tion, and depends on the content of initiation fac- 
tors IF-2 or IF-2B, respectively. As a qu~itative 
difference after growth stimulation, the ap- 
pearance of a novel 23 kDa cytosol protein was 
demonstrated. 
3. GROWTH-INHIBITING FACTORS 
Hitherto, peptide growth inhibitors, as a whole, 
have received much less attention than growth ac- 
tivators. Considering this, the progress de- 
monstrated at this symposium was impressive. 
J.C. Wang (East Lansing) described a 13 kDa 
protein (FGR-S) isolated from the conditioned 
medium of NIH-3T3 ~broblasts which at a con- 
centration of about 0.23 nM induces a decrease in 
the percentage of cells passing through S-phase. 
FGR-S is an endogenous cell product, synthesized 
and secreted by 3T3 cells. Using MoAbs to this 
protein, which are able to relieve density- 
dependent inhibition of 3T3 cells, the 13 kDa pro- 
tein was characterized as carrier of the growth in- 
hibitory activity. 
R. Grosse (Berlin-Buch) demonstrated the isola- 
tion from mammary tissue also of a 13 kDa 
growth inhibitor (MDGI) inhibiting proliferation 
of mammary epithelial cells at concentrations of 
about lo- ll-lO-‘o M. Interestingly, this protein 
shows immunological cross-reactivity with the in- 
hibitor from fibroblasts isolated by Wang. Exten- 
sive partial amino acid sequence analysis identifies 
this protein and shows its structural relatedness to 
a group of cellular proteins binding hydrophobic 
ligands, such as fatty acid-binding proteins and the 
cellular retinoic acid-binding protein. The reactivi- 
ty with such ligands might be involved in the action 
of this protein. The data strongly suggest that 
besides TGF-fl and the interferons, which are po- 
tent inhibitors of ceil proliferation, there might ex- 
ist a new class of growth inhibitors. 
P. Langen ~Berlin-Buch) referred to the an- 
tagonism of MDGI and growth factors and 
presented ata to indicate the possible involvement 
of ribonucleotide reductase in the intracellular ac- 
tion pathway of the factor. This enzyme might well 
be an important regulatory point of attack for 
natural and artificial regulators of cell pro- 
liferation. 
T.C. Johnson (Manhattan, Kansas) reported on 
the isolation and characterization of an 18 kDa 
sialoglycopeptide (SGP) which proved to be a po- 
tent inhibitor of both macromolecular metabolism 
and cell division in a variety of non-transformed 
cells, whereas several tumour cell lines were less 
reactive or almost resistant. The protein was 
shown to possess an intrinsic protease activity. It 
blocked bombesin-, EGF- or TPA-induced DNA 
synthesis in 3T3 cells. Addition of the 
Ca2+-ionophore A23 187 counteracted the in- 
hibitory influence of the glycopeptide. A cell sur- 
face interaction was shown to be sufficient for the 
inhibitory activity. 
C. Hare1 (Villejuif) presented experiments on the 
isolation of a 45 kDa protein from 3T3 cell condi- 
tioned medium, which inhibited DNA synthesis in- 
duced by tY-globulin and acted in the Cl-phase of 
the cell cycle. The preceding stimulation of RNA 
synthesis was also inhibited. 
A. Balacz (Budapest) showed the isolation of an 
inhibitor of bone marrow myeloid cell prolifera- 
tion from calf spleen. The inhibitor, which inhibits 
DNA synthesis in rat bone marrow ceils and 
thymocytes, also inhibited soft agar colony forma- 
tion of C50 Blach-mouse bone marrow cells and 
HL-60 myeloblasts. 
W. Birchmeier ~T~bingen) demonstrated an 
alternative approach to the problem of tumour cell 
growth inhibition. He selected MoAbs against 
melanoma cell membrane antigens which interfere 
with proliferation or metastasis of the tumour 
cells. These antibodies were used to identify an 
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80 kDa membrane protein involved in cell adhe- 
sion (possibly the already known L-CAM) and an 
83 kDa glycoprotein, which seems to be involved 
in inhibition of melanoma cell metastasis in mouse 
lungs and which is dramatically down-regulated by 
TGF-,&. 
The facts presented strengthened the hypothesis 
supported by most of the participants of the sym- 
posium that cell proliferation is regulated in vivo 
by the antagonistic action of growth-promoting 
and growth-inhibiting peptides. 
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